---
title: "Weekly Recap | AstraZeneca +3.9%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302169031.md"
description: "AstraZeneca (AZN) rallied 3.9% this week to close at $165.41, outperforming the S&P 500 by about 5.85 percentage points. The move was back-end loaded: shares slipped on Monday and Tuesday, touching an intraday low of $154.00, before rebounding over the next three sessions. Thursday’s high reached $169.81, with Friday giving back a little of the gain. The weekly range was 9.92%."
datetime: "2026-10-17T06:36:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302169031.md)
  - [en](https://longbridge.com/en/news/302169031.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302169031.md)
generator: "portal-rs"
---

# Weekly Recap | AstraZeneca +3.9%, most brokers rate it buy

## The Week

AstraZeneca (AZN) rallied 3.9% this week to close at $165.41, outperforming the S&P 500 by about 5.85 percentage points. The move was back-end loaded: shares slipped on Monday and Tuesday, touching an intraday low of $154.00, before rebounding over the next three sessions. Thursday’s high reached $169.81, with Friday giving back a little of the gain. The weekly range was 9.92%.

## Key Events

AstraZeneca pushed forward on both the pipeline and AI collaboration fronts. Early in the week, its rare disease asset efzimfotase alfa missed the key endpoint in the HICKORY Phase III trial for hypophosphatasia, but still showed a 17.05-metre improvement in six-minute walk test versus placebo. The company highlighted the signal as meaningful, and peak sales estimates for the bone disease drug were put around $5 billion. The same week, a new indication for ravulizumab was proposed for priority review.

From Wednesday, the company stepped up its tie-up with AI drug discovery player insitro. On Thursday, AstraZeneca paid $40 million upfront as part of a collaboration targeting fatty liver and heart diseases; on Friday, the deal was described as a $1.5 billion cardiovascular-metabolic partnership, with AstraZeneca securing exclusive global rights to advance certain selected programmes. The broader pharma sector also caught a bid from safe-haven demand and rotation into defensive names.

## Analyst Ratings

AstraZeneca is covered by 12 analysts, of whom 7 rate it buy, 3 rate it overweight, 1 rates it hold and 1 rates it sell. The consensus recommendation is buy, with a consensus target price of $207.16, roughly 25.24% above the current share price. Individual targets range from $158.00 to $240.00, pointing to a wide spread of views. Within its industry, AstraZeneca ranks 31st out of 203 names.

## The Week Ahead

The main company event is AstraZeneca’s third-quarter results due before market open on 30 October. Consensus estimates point to EPS of about $1.15 and revenue of roughly $16 billion. Before that, the US will release the NAHB housing market index on 19 October, then housing starts, building permits and EIA crude inventories over 20–21 October. Those macro prints may keep shaping the rotation between defensive and cyclical sectors.

## In Short

AstraZeneca bucked a weaker tape this week on pipeline news and fresh AI drug discovery commitments. The analyst base is largely constructive, and the consensus target sits above spot, while the latest session’s capital flow shows large-lot money as a net buyer. Still, the wide target range suggests the market remains split on how quickly pipeline and AI collaboration efforts will translate into earnings. The Q3 print will be the next test.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

- [Key facts: Panel Rejects AZ Breast Drug; FDA Approves Saphnelo](https://longbridge.com/en/news/284855561.md)
- [AstraZeneca Tracks Real-World Sinus Surgery Outcomes in China: What Investors Should Watch](https://longbridge.com/en/news/286132902.md)
- [NVTS: Claros completes a grid-to-XPU portfolio built to turn power efficiency into more AI compute](https://longbridge.com/en/news/302447528.md)
- [Oracle Corporation $ORCL Stock: Quadrant Capital Group LLC Decreases Position](https://longbridge.com/en/news/302555433.md)
- [Micron, Taiwan union sign deal, withdraw from mediation](https://longbridge.com/en/news/302521797.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**